AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease

Stock Information for AC Immune SA

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AC Immune SA

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.